A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

Brenda Wittman; John Horan; Joanna Baxter; John Goldberg; Raymond Felgar; Erin Baylor; Bean Cromwell; Nicholas Cross; John M. Bennett

doi:10.1016/j.leukres.2003.10.011

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

Brenda Wittman, John Horan, Joanna Baxter, John Goldberg, Raymond Felgar, Erin Baylor, Bean Cromwell, Nicholas Cross, John M. Bennett

Pediatrics

Research output: Contribution to journal › Article

18 Scopus citations

Abstract

Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

Original language	English (US)
Pages (from-to)	65-69
Number of pages	5
Journal	Leukemia Research
Volume	28
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/j.leukres.2003.10.011
State	Published - May 2004

Keywords

Atypical CML
ETV6-PDGFRB fusion gene
Imatinib mesylate
t(5;12)

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2003.10.011

Fingerprint Dive into the research topics of 'A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate'. Together they form a unique fingerprint.

Cite this

Wittman, B., Horan, J., Baxter, J., Goldberg, J., Felgar, R., Baylor, E., Cromwell, B., Cross, N., & Bennett, J. M. (2004). A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leukemia Research, 28(SUPPL. 1), 65-69. https://doi.org/10.1016/j.leukres.2003.10.011

@article{e23ef9689a464963b67e2561080f8e04,

title = "A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate",

abstract = "Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.",

keywords = "Atypical CML, ETV6-PDGFRB fusion gene, Imatinib mesylate, t(5;12)",

author = "Brenda Wittman and John Horan and Joanna Baxter and John Goldberg and Raymond Felgar and Erin Baylor and Bean Cromwell and Nicholas Cross and Bennett, {John M.}",

year = "2004",

month = may,

doi = "10.1016/j.leukres.2003.10.011",

language = "English (US)",

volume = "28",

pages = "65--69",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "SUPPL. 1",

}

TY - JOUR

T1 - A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

AU - Wittman, Brenda

AU - Horan, John

AU - Baxter, Joanna

AU - Goldberg, John

AU - Felgar, Raymond

AU - Baylor, Erin

AU - Cromwell, Bean

AU - Cross, Nicholas

AU - Bennett, John M.

PY - 2004/5

Y1 - 2004/5

N2 - Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

AB - Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

KW - Atypical CML

KW - ETV6-PDGFRB fusion gene

KW - Imatinib mesylate

KW - t(5;12)

UR - http://www.scopus.com/inward/record.url?scp=1342279448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342279448&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.10.011

DO - 10.1016/j.leukres.2003.10.011

M3 - Article

C2 - 15036944

AN - SCOPUS:1342279448

VL - 28

SP - 65

EP - 69

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - SUPPL. 1

ER -